For patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast ...

The Phase III study saw the drug able to cut the risk of disease progression or death by 38% with imlunestrant alone, and ...

An experimental drug stops advanced breast cancer from progressing in some people with tumors that have grown resistant to ...

Data from a late-stage study shows that LLY's experimental oral drug benefited certain breast cancer patients when used as ...

Eli Lilly announces positive Phase III EMBER-3 trial results for imlunestrant in advanced breast cancer, showing a 38% ...

Komal Jhaveri, MD, FACP, breast oncologist and early drug development specialist at Memorial Sloan Kettering Cancer Center, ...

While other big pharmas have faltered, Lilly made headway in a Phase 3 trial that could provide a treatment option to replace ...

It looks like Eli Lilly’s oral selective estrogen receptor degrader (SERD) imlunestrant may need some extra help to reach a ...

Eli Lilly (LLY) reported positive Phase 3 data for its drug candidate imlunestrant as both a combination and monotherapy in ...

A groundbreaking international study has found that imlunestrant plus abemaciclib significantly improved progression-free survival (PFS) versus imlunestrant monotherapy in patients with estrogen ...

Interim overall survival (OS) analyses at 31% maturity in patients with ESR1 mutations, and 23% maturity among all patients, ...

Eli Lilly (LLY) announced results from the Phase 3 EMBER-3 study of imlunestrant, an investigational, oral selective estrogen receptor ...